Phase 2
Completed N=33
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
Source: ClinicalTrials.gov NCT02762370 ↗Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcomePrimary: Change From Baseline for Average Blood Glucose (mg/dL) — 14.66; 33.88 mg/dL — p=0.0452
Summary
The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with osteoarthritis (OA) of the knee and Type 2 diabetes mellitus (DM).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline for Average Blood Glucose (mg/dL) |
14.66; 33.88 | 0.0452 sig |
| SECONDARY Percent Time Blood Glucose Less Than 70 mg/dl, 70 - 180 mg/dl, 180.1 - 250.0 mg/dl, 250.1 - 350.0 mg/dl, and Greater Than 350.0 mg/dl |
1.2; 0.3; 64.1; 42.7; 23.0; 27.4 | — |
| SECONDARY Glycemic Variability Coeffecient of Variation (CV) |
22.43; 27.05 | — |
| SECONDARY Area Under the Effect (AUE) Curves for Average Blood Glucose - FX006 Versus TCA IR |
22089.0; 23669.1; 3703.3; 4483.2; 7902.6; 9251.7 | — |
Eligibility Criteria
Inclusion Criteria
- Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions
- Male or female ≥40 years of age
- Type 2 diabetes mellitus for at least 1 year prior to Screening and not managed with injectable agents (e.g. insulin or insulin analogs, exenatide, pramlintide, liraglutide)
- Currently treated with 1 or 2 oral agents for diabetes, with stable doses for at least 2 months
- HbA1c ≥6.5% and ≤ 9.0%
- Currently meets American College of Rheumatology (ACR) Criteria (clinical or radiological) for OA.
- Symptoms associated with OA of the knee for ≥ 6 months prior to Screening
- Index knee pain on most days (>15) over the last month (as reported by the patient)
- Body mass index (BMI) ≤ 40 kg/m2
- Willingness to abstain from use of protocol-specified restricted medications during the study
- Willingness to wear a CGM device uninterrupted for 24 hours per day throughout the study, remain with receiving range and comply with calibration requirements
- Accustomed to using a Standard Blood Glucose Measuring device by finger stick
Exclusion Criteria
- Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or arthritis associated with inflammatory bowel disease
- History of infection in the index knee joint
- Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening
- Presence of surgical hardware or other foreign body in the index knee
- Unstable joint (such as a torn anterior cruciate ligament) within 12 months of screening
- IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening
- IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening
- IV or intramuscular (IM) corticosteroids (investigational or marketed) within 3 months of Screening
- Oral corticosteroids (investigational or marketed) within 1 month of Screening
- Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
- Any other IA investigational drug/biologic within 6 months of Screening
- Prior use of FX006
- Use of acetaminophen, or acetaminophen containing products
- Current use of a continuous glucose monitoring device
- Women of child-bearing potential not using effective contraception or who are pregnant or nursing
Data sourced from ClinicalTrials.gov (NCT02762370). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.